What is Hyperfine's latest dividend and current dividend yield?

What were the key takeaways from Hyperfine's earnings call?

What does Hyperfine do and what are its main business segments?

What factors drove the changes in Hyperfine's revenue and profit?

What is Hyperfine's gross profit margin?

What were the key takeaways from Hyperfine’s earnings call?

What is the revenue and EPS growth rate for Hyperfine year over year?

Did Hyperfine beat or miss consensus estimates last quarter?

- **Revenue Surge**: Q4 2025 revenue up 128% YoY to $5.3 million, with 16 next-gen Swoop systems sold. Full-year 2025 revenue grew 5% to $13.6 million. 
- **Gross Margin Expansion**: Q4 gross margin 50.9% (vs. 38.6% prior), full-year 49.8% (+410bps YoY). 
- **Clinical Validation**: 98% MRI concordance in neurology offices, 1-1.5 year ROI for hospitals, and 4x patient preference for portable MRI. 
- **2026 Outlook**: $20-22 million revenue (+55% midpoint), 50-55% gross margin, $26-28 million cash burn. 
- **Key Drivers**: Multi-unit IDN deals, India expansion, and segmented pricing strategy ($590k MSRP for hospitals, $550k for offices).

**【CEO Summary Section】**
- Q4 2025 revenue reached $5.3 million, up 128% YoY, driven by 16 next-gen Swoop system sales (vs. 9 in Q4 2024). Full-year 2025 revenue was $13.6 million (+5% YoY). 
- Next-gen Swoop system adoption accelerated in critical care (ED, neurology offices) and expanded into India (FDA cleared) and Europe (CE pending). 
- Clinical validation: 98% concordance with high-field MRI in neurology offices (NEURO-PMR study), 1-1.5 year ROI for hospitals (Jefferson Abington data), and 4x patient preference for portable MRI. 
- Pipeline momentum: multi-unit IDN deals progressing, 20% enrollment in contrast-enhanced MRI study (targeting 2026 FDA submission). 
- Gross margin expanded to 50.9% in Q4 (vs. 38.6% in Q4 2024), with full-year margin at 49.8% (+410bps YoY). 

**【CFO Financial Commentary】**
- 2025 cash burn reduced 22% YoY to $29.9 million, with Q4 burn down 30% YoY to $5.7 million. 
- 2026 guidance: $20-22 million revenue (+55% midpoint YoY), 50-55% gross margin, $26-28 million cash burn. 
- Balance sheet: $35.1 million cash as of Q4, plus $15 million debt tranche extending runway to 2028. 
- R&D/S&M expenses down 22-25% YoY, reflecting operational efficiency. 

**【Q&A Highlights】**
- **Pipeline & Pricing**: 2026 revenue growth driven by multi-unit IDN deals (e.g., 3-4 units/hospital), $590k MSRP for next-gen systems (vs. $550k prior), and segmented pricing for neurology offices ($550k Model 1 vs. $590k Model 2). 
- **Service Revenue**: Q4 decline due to one-time contract adjustments, but expect growth as installed base expands. 
- **Market Dynamics**: Neurology offices (10% of practices with MRI) and India (new regulatory approvals) offer high-growth opportunities. 
- **Execution Risk**: IDN deals may cause quarterly lumpiness due to budget cycles, but 2026 revenue expected to strengthen sequentially.

Hyperfine, Inc.(HYPR)-20260319-2025 Q4 Earnings call transcript

- **Revenue Acceleration**: Q3 $3.4M (+27% QoQ), Q4 guided $5-6M (+60% QoQ), full year $13-14M (+137% YoY)
- **Margin Expansion**: Gross margin 53.8% (up 450bp QoQ), 2025 full year 49-51% (up 430bp YoY)
- **Pipeline Diversification**: 3 verticals (hospitals, offices, international) with 8 units sold in Q3, 10 language OPTI AI rollouts
- **Cash Efficiency**: Q3 cash burn $5.9M (-27% QoQ), 2025 full year $29-31M (-22% YoY), runway to H2 2027 with $20M raise
- **Strategic Wins**: France Uni HA tender, India regulatory pending, 10 language OPTI AI launch

**【CEO Summary Section】**
- Q3 2025 revenue reached $3.4 million, up 27% sequentially, driven by next-generation Swoop system sales and a record average selling price of $361,000.
- Gross margin improved to 53.8%, up 450 basis points sequentially, due to higher ASP and cost optimization.
- Launched OPTI AI software in 10 languages, with CE and UKCA approvals, and expanded into international markets like France and India.
- Diversified pipeline across 3 verticals: hospitals (IDN deals), neurology offices (Neuro Net partnerships), and international (tender processes).
- Q4 2025 revenue guidance: $5-6 million (60% sequential growth), full year 2025: $13-14 million.

**【CFO Commentary】**
- Q3 2025 financials: 
  - Revenue: $3.4M (27% sequential growth)
  - Gross profit: $1.8M (53.8% margin)
  - R&D: $4.0M (11% sequential decline)
  - SGA: $6.7M (4.7% sequential increase)
  - Net loss: $11.0M ($0.14/share)
  - Cash burn (excl. financing): $5.9M (27% sequential decline)
- Full year 2025 guidance: 
  - Revenue: $13-14M (137% YoY growth)
  - Gross margin: 49-51% (430bp YoY expansion)
  - Cash burn: $29-31M (22% YoY decline)
  - Cash runway extended to H2 2027 with $20M October equity raise.

**【Q&A Highlights】**
- **Pipeline Segmentation**: 
  - Hospitals: 8 units sold in Q3, expanding to 2+ hospitals per IDN
  - Offices: 2 large neurology practices in pilot, 10 language OPTI AI rollouts
  - International: France (Uni HA tender), India (pending regulatory)
- **Growth Drivers**: 
  - Hospital: 1-1.5 year ROI vs. 3-4 years for high-field MRI
  - Office: 15% ASP premium, 100M+ neurology patients
  - International: 10 language support, 2026 CE Mark for urology
- **2026 Outlook**: 
  - Q4 2025 results will set 2026 trajectory; no guidance yet
  - Focus on scaling commercial infrastructure, not R&D

Hyperfine, Inc. (HYPR) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 2025 revenue up 26% to $2.7M, fueled by 8 system sales including first next-gen Swoop. 
- **Margin Breakthrough**: Gross margin jumps 800bps to 49%, cash burn down 19%. 
- **Product Momentum**: Next-gen Swoop system with Optive AI launched 10 weeks ago, already generating 100+ pipeline deals. 
- **Growth Drivers**: U.S. hospitals (+15% ASP), neurology offices (100+ study patients), and international expansion (3 markets launched). 
- **2025 Outlook**: 10-20% revenue growth, 47-50% margins, $27-29M cash burn, with accelerating Q3/Q4 growth.

**【CEO Summary Section】**
- Q2 2025 revenue: $2.7 million (26% sequential growth), driven by 8 system sales, including first next-gen Swoop system. 
- Gross margin improved 800bps to 49%, with cash burn down 19% sequentially to $8.1 million.
- Key milestones: FDA clearance for 2 new technologies, completion of office pilot program, and launch of next-gen Swoop system with Optive AI software.
- Expansion into 3 channels: U.S. hospitals, neurology offices, and international markets (Canada, Australia, New Zealand, India pending approval).
- 2025 outlook: Strong second-half growth with sequential revenue step-ups, targeting 10-20% full-year revenue growth.

**【CFO Financial Commentary】**
- Q2 2025 financials: 
  - Revenue: $2.7M (26% sequential growth)
  - Gross margin: 49.3% (vs. 31.3% Q1)
  - Net loss: $9.2M ($0.12/share)
  - Cash burn: $8.1M (19% sequential decline)
- 2025 guidance: 
  - Revenue: 10-20% growth vs. 2024
  - Gross margin: 47-50% (280bps YoY improvement)
  - Cash burn: $27-29M (27% YoY decline)
- Highlights: 
  - New Swoop system MSRP: $550K (+15% vs. prior gen)
  - R&D/SG&A expenses down 10% sequentially
  - Cash runway extended to end-2026

**【Q&A Key Highlights】**
- **Revenue Growth Path**: Q3 sequential growth to be 50% greater than Q1/Q2, with accelerating momentum in Q4. 
- **Next-gen Swoop Launch**: 100+ pipeline deals, focusing on new system sales (+15% ASP) vs. upgrades. 
- **Office Market Traction**: 100+ patients enrolled in Neuro PMR study (ahead of schedule), with focus on utilization rates (>10 scans/day). 
- **International Expansion**: Optive AI software launched in 3 markets, next-gen hardware to follow in H2 2026. 
- **ASP Dynamics**: 26% sequential revenue growth driven by 8% unit growth and 17% ASP increase.

Hyperfine, Inc. (HYPR) Q2 2025 Earnings Call Transcript

- **Q1 2025 Results**: $2.1M revenue, 41.3% gross margin, $9.4M net loss
- **Office Business Breakthrough**: 5+ pilot sites operational, NEURO PMR study 50% enrolled
- **Tech Upgrade**: 1.5T MRI-equivalent image quality software launching Q3
- **2025 Growth Drivers**: Office business (mid-2025), India market entry, 47-50% gross margin target
- **Risk Factors**: U.S. hospital deal delays, academic grant funding uncertainty, long sales cycles

**【CEO Opening Remarks】**
- Q1 2025 revenue: $2.1 million (6 units sold) with strong average selling price of $350k.
- Key initiatives:
  - **Office business launch**: 5+ pilot sites now IAC-accredited, scanning patients, and navigating CMS reimbursement.
  - **NEURO PMR study**: 100-patient neurology office study 50% enrolled, targeting Q3 2025 completion.
  - **Next-gen tech rollout**: Software upgrade for 1.5T MRI-equivalent image quality expected Q2 2025, commercial launch Q3.
  - **International expansion**: India regulatory approval anticipated Q2, distributor pipeline growing in Europe/Asia.
- 2025 outlook: "Two-halves" narrative - Q1 constrained by U.S. hospital delays, Q2+ driven by office launch, international growth, and tech upgrades.

**【CFO Financial Update】**
- Q1 2025 financials:
  - Revenue: $2.1M (down 18% YoY)
  - Gross margin: 41.3% (up 20bps YoY)
  - Net loss: $9.4M ($0.12/sh)
  - Cash burn: $10.1M (16% YoY decline)
  - Cash balance: $33.1M (includes $6M Feb 2025 raise)
- Updated 2025 guidance:
  - Revenue: $10-20% growth vs 2024
  - Gross margin: 47-50% (vs 39% in 2024)
  - Cash burn: $25-28M (31% YoY decline)
- Key metrics improvement:
  - R&D/Sales expense ratio down 10% YoY
  - Operating leverage optimization (cash runway to end-2026)

**【Q&A Key Takeaways】**
1. **Office business viability**:
   - Neurologists report ease of use, incremental clinical value
   - 500-600 annual MRI referrals per office
   - Flexible payment models (e.g., revenue share)
2. **Hospital sales challenges**:
   - Academic grants delays causing Q1 deal losses
   - Average sales cycle now 12-18 months
   - Multiple-unit hospital deals growing in pipeline
3. **International momentum**:
   - Distributor pipeline expanding in Europe/Middle East/Asia
   - India market entry on track for Q2
   - No material tariff impact to date
4. **2025 revenue visibility**:
   - Q2+ driven by office launch (mid-2025) and India entry
   - Hospital deals remain unpredictable but pipeline robust

Hyperfine, Inc. (HYPR) Q1 2025 Earnings Call Transcript

- **Strong 2024 Execution**: 17% revenue growth, 300bps margin expansion, and 9% cash burn reduction
- **2025 Growth Engine**: 
  - Office launch by mid-2025 with 1.5T MRI-equivalent image quality 
  - International sales now 50% of mix 
  - $6B U.S. TAM across hospital and office settings
- **Financial Strength**: $37.6M cash on hand with runway to end-2026
- **Product Differentiation**: 10th/11th gen Swoop systems to close image quality gap with conventional MRI

**【CEO Opening Remarks】**
- **2024 Financial Highlights**: Revenue of $12.9M (+17% YoY), gross margin expansion to 46%, and reduced net cash burn to $38.4M (-9% YoY). 
- **Strategic Reorganization**: $6M capital raise extends cash runway to end-2026. 
- **2025 Growth Catalysts**: 
  1. Launch Swoop in neurology offices by mid-2025 (FDA-cleared for all brain MRI scans) 
  2. Expand multi-site hospital sales (e.g., ER, ICU, OR) 
  3. Accelerate international market adoption 

**【CFO Financial Review】**
- **Q4 2024 Results**: 
  - Revenue: $2.3M (-15% YoY) due to delayed U.S. hospital deals and lower ASP mix 
  - Gross Profit: $0.8M (-20% YoY) from lower sales volume 
  - R&D/Sales Expenses: $5.1M and $6.5M (flat YoY) 
  - Net Loss: $10.4M (-3% YoY) 
- **Full Year 2024**: 
  - Organic revenue growth 70% (excluding one-time London sale) 
  - Gross margin +300bps to 46% 
  - OpEx down 12% to $26.6M 

**【Product Update & Strategy】**
- **Next-Gen Swoop Systems**: 
  - 10th/11th gen software to launch mid-2025 with 1.5T MRI-equivalent image quality 
  - KOL feedback: "game-changing" for new users with shorter learning curve 
- **Market Expansion**: 
  - U.S. TAM >$6B (hospital + office) 
  - International sales now 50% of mix (vs. 0% in 2023) 
  - IAC accreditation for office-based portable MRI


Hyperfine (HYPR)-17 Mar 25-2024 Q4 Earnings call transcript

Hyperfine (HYPR)-12 Nov 24-2024 Q3 Earnings call transcript

Hyperfine Inc - Ordinary Shares (HYPR)-8 Aug 24-2024 Q2 Earnings call transcript

Hyperfine Inc - Ordinary Shares (HYPR)-13 May 24-2024 Q1 Earnings call transcript

- **Revenue Surge**: Q4 2023 revenue up 89% YoY to $2.7 million; FY2023 revenue up 62% to $11 million, driven by 7 Swoop system sales.
- **Gross Margin Expansion**: FY2023 gross margin improved to 43.1%, with 2024 guidance of 45-50%.
- **Alzheimer's Breakthrough**: CARE PMR study evaluates Swoop's role in monitoring amyloid-targeting therapies, targeting a $50 billion market.
- **2024 Outlook**: Guided for $12-15 million revenue and $40 million cash burn, supported by strong Q1 pipeline and disciplined spending.
- **International Expansion**: Distributor-led growth in CE/UKCA markets preserves cash while capturing incremental opportunities.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2023 revenue of $2.7 million, up 89% YoY; FY2023 revenue of $11 million, up 62% YoY. Key driver: 7 Swoop system sales in the U.S., with record ASPs.
- **Strategic Focus**: 2024 priorities include expanding use cases (stroke, Alzheimer's), international market entry, and maintaining strong gross margins (43.1% in FY2023).
- **Alzheimer's Initiative**: Launched CARE PMR study to evaluate Swoop's role in monitoring amyloid-targeting therapies (e.g., LEQEMBI). Expected data readout by end-2024.
- **Innovation**: Received FDA clearance for AI-powered software update, improving image quality and ease of use. 8th FDA clearance since 2020.
- **Commercial Momentum**: Sold systems to flagship institutions like NYU Langone, Stanford, and Children's Hospital of Philadelphia. Expanded into critical care, emergency, and pediatric settings.

**【CFO Financial Commentary】**
- **FY2023 Financials**: Net loss of $44.3 million (down 39.5% YoY); cash burn of $42 million (down 40% YoY). Ended with $75.2 million in cash.
- **2024 Guidance**: Revenue $12-15 million; gross margin 45-50%; cash burn ~$40 million. Q1 2024 revenue expected >$3 million.
- **Expense Management**: R&D down 20% YoY; SG&A down 35% YoY. Maintaining disciplined spending while investing in growth.

**【Q&A Highlights】**
- **Q4 Revenue Variability**: Deal closure delays impacted Q4, but Q1 2024 pipeline is strong. FY2024 guidance reflects balanced investment in R&D, clinical evidence, and commercialization.
- **International Strategy**: Expanding via third-party distributors in CE/UKCA-marked regions. Focus on preserving cash while capturing incremental opportunities.
- **Alzheimer's Program**: No regulatory hurdles; leveraging existing FDA clearance. CARE PMR study aims to simplify imaging workflows for ATT patients.
- **Cash Runway**: Current cash (~$75 million) supports operations into early 2026. Management confident in achieving 2024 targets with disciplined execution.

Actual	-2.73	-0.34	-0.33	-0.19	-0.19	-0.17	-0.15	-0.15	-0.15	-0.14	-0.14	-0.14	-0.14	-0.12	-0.12	-0.14	-0.06
Forecast		-0.21	-0.3	-0.2567	-0.2194	-0.13	-0.17	-0.1667	-0.1808	-0.1467	-0.14	-0.14	-0.1403	-0.1175	-0.12	-0.105	-0.08
Surprise	0.00%	-61.90%	-10.00%	+25.98%	+13.40%	-30.77%	+11.76%	+10.02%	+17.04%	+4.57%	0.00%	0.00%	+0.21%	-2.13%	0.00%	-33.33%	+25.00%

HYPR

HYPR fundamentals

HYPR Q4 2025 Earnings

Earnings Call

You can ask Aime

HYPR

HYPR fundamentals

HYPR Q4 2025 Earnings

Earnings Call

HYPR Earnings Call Summary for Q4/20254:30 PM on Mar 18, 2026

HYPR Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

HYPR Earnings Call Summary for Q2/20254:30 PM on Aug 13, 2025

HYPR Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

HYPR Earnings Call Summary for Q4/20244:30 PM on Mar 17, 2025

You can ask Aime